Checkmate Pharmaceuticals, Inc.
CIK 0001651431
Revenue (TTM)
—
Q1 May 2022
Net Income (TTM)
−$63.93M
−66.4% YoY
Q1 May 2022
EPS Diluted (TTM)
—
Q1 May 2022
Gross Margin
—
Q1 May 2022
Operating Margin
—
Q1 May 2022
Net Margin
—
Q1 May 2022
Free Cash Flow (TTM)
−$54.56M
Q1 May 2022
Cash
$39.48M
Q1 May 2022
Total Debt
—
Q1 May 2022
Shares Outstanding
22.04M sh
Q1 May 2022
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.